Phase 1 study of SLV-154, small molecule inhibitor with undefined MOA.

This Phase 1 dose-escalation study by Solve Therapeutics in Saint Louis evaluates SLV-154 as a monotherapy for patients with metastatic, progressive solid tumors including SCCHN, sarcoma, breast, cervical, endometrial, ovarian, SCLC, NSCLC, and urothelial cancers. The trial aims to assess safety, pharmacokinetics, pharmacodynamics, immunogenicity, and early efficacy, representing a first-in-human evaluation of an investigational small molecule inhibitor with an undefined mechanism of action.